U.K. price watchdog changes its tune on BMS melanoma blockbuster Yervoy | PharmaBoardroom

U.K. price watchdog changes its tune on BMS melanoma blockbuster Yervoy

face
TAGS: ,

Three months after Britain's National Institute for Health and Care Excellence said it would not recommend Bristol-Myers Squibb's Yervoy as a first-line treatment for melanoma, the much-feared cost-effectiveness agency has changed its mind. A new draft guidance from NICE now says Yervoy should be available as the first choice for treating patients with advanced melanoma.

Latest Report